Bristol-Myers Squibb Company
Короткая

HISTORY REPEATS ITSELF: SHORT BMY

163
BMY is showing erie similarities of its last major cycle, and it appears massive downside is on the horizon. Decreasing RSI, strong support and resistance and the exact same chart pattern are more than enough to show BMY is likely headed down at least 20% over the next few months.

Sizable downside in the overall market over the next few months will likely add to the selling pressure. Price target is $32 by Q4 2019.

Отказ от ответственности

Информация и публикации не предназначены для предоставления и не являются финансовыми, инвестиционными, торговыми или другими видами советов или рекомендаций, предоставленных или одобренных TradingView. Подробнее читайте в Условиях использования.